Description: RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
Home Page: www.radnet.com
1510 Cotner Avenue
Los Angeles,
CA
90025
United States
Phone:
310 478 7808
Officers
| Name | Title |
|---|---|
| Dr. Howard G. Berger M.D. | Chairman, President & CEO |
| Mr. Mark D. Stolper | Executive VP & CFO |
| Dr. A. Gregory Sorensen M.D. | Executive VP, Chief Science Officer & Director |
| Mr. Mital Patel | Executive VP of Financial Planning & Analysis and Chief Administrative Officer |
| Mr. Norman R. Hames | President & COO of Western Operations |
| Mr. Stephen M. Forthuber | President & COO of Eastern Operations |
| Ms. Christine Nayoma Gordon | Senior VP of Operations of Northern California |
| Mr. Ranjan Jayanathan | Executive VP, Chief Information Officer & GM of eRAD - Radiology Information Technology Division |
| Ms. Laura Foster BSRT, MPH, J.D. | Senior Vice President of Compliance & Regulatory Affairs |
| Mr. David Jeffrey Katz | Executive VP, Chief Legal Officer & Corporate Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.5204 |
| Price-to-Sales TTM: | 3.1442 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10000 |